137 related articles for article (PubMed ID: 31233307)
1. Addressing oncologists' gaps in the use of biosimilar products.
Williamson C; Berger L; Sullivan TP; Crawford J; Lyman GH
Am J Manag Care; 2019 Jun; 25(6 Spec No.):SP188-SP191. PubMed ID: 31233307
[No Abstract] [Full Text] [Related]
2. Biosimilar Filgrastim Use in the United States vs the European Union and Japan-Why Does It Lag Behind and What Can Be Done?
Qureshi ZP; Nagai S; Bennett CL
JAMA Oncol; 2019 Mar; 5(3):297-298. PubMed ID: 30508013
[No Abstract] [Full Text] [Related]
3. BIOSIMILAR DRUGS ARE NOT GENERICS.
Zangeneh F; Dolinar R
Endocr Pract; 2016 Jan; 22(1):6-7. PubMed ID: 26731083
[No Abstract] [Full Text] [Related]
4. Opportunities and challenges in biosimilar uptake in oncology.
Dolan C
Am J Manag Care; 2018 Jun; 24(11 Suppl):S237-S243. PubMed ID: 29957909
[TBL] [Abstract][Full Text] [Related]
5. Perception of hematologists and oncologists about the biosimilars: A prospective Tunisian study based on a survey.
Hadoussa S; Bouhlel M; Soussi MA; Drira C; Hadoussa M; Khrouf MR
J Oncol Pharm Pract; 2020 Jan; 26(1):124-132. PubMed ID: 31106664
[TBL] [Abstract][Full Text] [Related]
6. What do oncologists need to know about biosimilar products?
Leung LK; Mok K; Liu C; Chan SL
Chin J Cancer; 2016 Oct; 35(1):91. PubMed ID: 27733189
[TBL] [Abstract][Full Text] [Related]
7. Rationale, Opportunities, and Reality of Biosimilar Medications.
Lyman GH; Zon R; Harvey RD; Schilsky RL
N Engl J Med; 2018 May; 378(21):2036-2044. PubMed ID: 29791832
[No Abstract] [Full Text] [Related]
8. NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020.
Becker PS; Griffiths EA; Alwan LM; Bachiashvili K; Brown A; Cool R; Curtin P; Dinner S; Gojo I; Hicks A; Kallam A; Kidwai WZ; Kloth DD; Kraut EH; Landsburg D; Lyman GH; Miller R; Mukherjee S; Patel S; Perez LE; Poust A; Rampal R; Rosovsky R; Roy V; Rugo HS; Shayani S; Vasu S; Wadleigh M; Westbrook K; Westervelt P; Burns J; Keller J; Pluchino LA
J Natl Compr Canc Netw; 2020 Jan; 18(1):12-22. PubMed ID: 31910384
[TBL] [Abstract][Full Text] [Related]
9. First biosimilar drug approved in the USA.
Burki TK
Lancet Oncol; 2015 Apr; 16(4):e161. PubMed ID: 25773170
[No Abstract] [Full Text] [Related]
10. Emerging Opportunities and Challenges of Biosimilars in Oncology Practice.
Lyman GH
J Oncol Pract; 2017 Sep; 13(9_suppl):7s-9s. PubMed ID: 28898591
[No Abstract] [Full Text] [Related]
11. Oncologists' confidence in knowledge of fertility issues for young women with cancer.
Duffy C; Allen SM; Dube C; Dickersin K
J Cancer Educ; 2012 Jun; 27(2):369-76. PubMed ID: 22259068
[TBL] [Abstract][Full Text] [Related]
12. Understanding State Regulation of Biosimilars and Effect on Prescribers.
Yale K; Awosika O; Rengifo-Pardo M; Ehrlich A
J Drugs Dermatol; 2017 Oct; 16(10):995-1000. PubMed ID: 29036253
[TBL] [Abstract][Full Text] [Related]
13. First US biosimilar launch.
Nat Biotechnol; 2015 Oct; 33(10):1013. PubMed ID: 26448071
[No Abstract] [Full Text] [Related]
14. Practice patterns and guideline adherence of medical oncologists in managing patients with early breast cancer.
Foster JA; Abdolrasulnia M; Doroodchi H; McClure J; Casebeer L
J Natl Compr Canc Netw; 2009 Jul; 7(7):697-706. PubMed ID: 19635225
[TBL] [Abstract][Full Text] [Related]
15. Medical Oncologists' Knowledge and Perspectives on the Use of Biosimilars in the United States.
Peipert JD; Kaiser K; Kircher S; Greene GJ; Shaunfield S; Hauner K; Cella D; Mroczek DK
JCO Oncol Pract; 2023 Mar; 19(3):e457-e464. PubMed ID: 36623249
[TBL] [Abstract][Full Text] [Related]
16. Oncologists' opinion of ethics committees functioning in Italy.
Apolone G; Mosconi P; Cattaneo G; Pomodoro L; Garattini S
Ann Oncol; 2002 Jul; 13(7):1157-8. PubMed ID: 12176797
[No Abstract] [Full Text] [Related]
17. Little information about fertility preservation is provided for cancer patients: A survey of oncologists' knowledge, attitude and current practice.
Vesali S; Navid B; Mohammadi M; Karimi E; Omani-Samani R
Eur J Cancer Care (Engl); 2019 Jan; 28(1):e12947. PubMed ID: 30421553
[TBL] [Abstract][Full Text] [Related]
18. Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians.
Cohen H; Beydoun D; Chien D; Lessor T; McCabe D; Muenzberg M; Popovian R; Uy J
Adv Ther; 2017 Jan; 33(12):2160-2172. PubMed ID: 27798772
[TBL] [Abstract][Full Text] [Related]
19. Biosimilars: what the oncologist should know.
Thill M; Thatcher N; Hanes V; Lyman GH
Future Oncol; 2019 Apr; 15(10):1147-1165. PubMed ID: 30793950
[TBL] [Abstract][Full Text] [Related]
20. Barriers to biosimilar utilization in the United States.
Dalpoas SE; Socal M; Proctor C; Shermock KM
Am J Health Syst Pharm; 2020 Nov; 77(23):2006-2014. PubMed ID: 33091103
[No Abstract] [Full Text] [Related]
[Next] [New Search]
